Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab Extension in Relapsing MS
NCT03381170Phase 2Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jun 2017
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ublituximab in multiple sclerosis (MS), sponsored by TG Therapeutics, Inc. Primary endpoint: Number of participants with treatment-related events as assessed by CTCAE V4.0 at 96 weeks. Started Jun 2017; status: completed.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03381170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381170.